EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Zhaoke Ophthalmology's enterprise value is HK$-532.93 Mil.
Zhaoke Ophthalmology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-411.88 Mil. Therefore, Zhaoke Ophthalmology's EV-to-EBITDA for today is 1.29.
The historical rank and industry rank for Zhaoke Ophthalmology's EV-to-EBITDA or its related term are showing as below:
HKSE:06622'
s EV-to-EBITDA Range Over the Past 10 Years
Min: -0.89 Med: 1.31 Max: 1.49
Current: 1.29
During the past 5 years, the highest EV-to-EBITDA of Zhaoke Ophthalmology was 1.49. The lowest was -0.89. And the median was 1.31.
HKSE:06622's EV-to-EBITDA is ranked better than 65.85% of 451
companies
in the Biotechnology industry
Industry Median: 9.15
vs HKSE:06622: 1.29
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
Zhaoke Ophthalmology EV-to-EBITDA Historical Data
The historical data trend for Zhaoke Ophthalmology's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Zhaoke Ophthalmology's EV-to-EBITDA
For the Biotechnology subindustry, Zhaoke Ophthalmology's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zhaoke Ophthalmology's EV-to-EBITDA Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zhaoke Ophthalmology's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Zhaoke Ophthalmology's EV-to-EBITDA falls into.
Zhaoke Ophthalmology's current Enterprise Value is HK$-532.93 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-411.88 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Zhaoke Ophthalmology's PE Ratio for today is calculated as:
Zhaoke Ophthalmology's share price for today is HK$1.49.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Zhaoke Ophthalmology's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was HK$-0.776.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Thank you for viewing the detailed overview of Zhaoke Ophthalmology's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
Zhaoke Ophthalmology (HKSE:06622) Business Description
Zhaoke Ophthalmology Ltd is an ophthalmic pharmaceutical company. It is dedicated to the research, development, and commercialization of therapies that address unmet medical needs in China. The company has built a comprehensive ophthalmic drug pipeline of 26 candidates that covers ocular indications affecting the front and the back of the eye, through either in-house development or in-licensing. It has also established an ophthalmic manufacturing facility and is assembling an experienced marketing team in anticipation of a near-term product launch.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
HKSE:06622 has been successfully added to your 